McKesson Corporation (MCK)
NYSE · Irving, Texas, USA · Founded 1833 · CEO Brian Tyler
Valuation summary
$1,093.66 fair value versus $1,062.16 in the market, a difference of +3.0%. Rated Hold.
| Fair value per share | $1,093.66 |
| Current share price | $1,062.16 |
| Upside / downside | +3.0% |
| Bear case | $25.50 |
| Bull case | $3,545.70 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.60% |
| Market capitalisation | $124B |
| EV / Sales | 0.3x |
About McKesson Corporation
Founded in 1833 in New York as a wholesale drug importer, making it one of the oldest companies in American healthcare. Brian Tyler has been CEO since 2019. McKesson distributes pharmaceuticals to pharmacies, hospitals and physician practices, moving an enormous volume of product on very thin margins. Its oncology business, which supports community cancer practices, is the higher-margin growth engine.
Investment case
- Distribution is an oligopoly of three, with scale barriers that make new entry impractical.
- Oncology and specialty distribution carry better margins than commodity drug distribution.
- GLP-1 drug volumes have driven substantial revenue growth through the distribution network.
Key risks
- Operating margins are around 1%, so small disruptions have outsized effects.
- Opioid litigation settlements represent a multi-billion dollar obligation over many years.
- Revenue growth is driven by drug prices and volumes it does not control.
Recent developments
- 2026-08-05 · McKesson names its Medical-Surgical Solutions business Wellverse ahead of the planned separation source
- 2026-08-05 · Fiscal Q1 2027 revenue $105.4bn, up 8%; adjusted EPS $9.93, up 20%; full-year adjusted EPS guidance raised to $44.20-$45.00 source
Revenue by segment
| US Pharmaceutical | 89% |
| Prescription Technology | 5% |
| Medical-Surgical & International | 6% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $452.7B | $4.4B |
| Year 2 | $489.8B | $5.3B |
| Year 3 | $529.9B | $6.3B |
| Year 4 | $573.3B | $7.4B |
| Year 5 | $620.2B | $8.7B |
What the street says
Viewed as a steady, defensive compounder. In August 2026 McKesson raised fiscal 2027 adjusted EPS guidance to $44.20-$45.00 after a 20% rise in first-quarter adjusted EPS, with Oncology & Multispecialty revenue up 33%. The planned separation of Medical-Surgical, now named Wellverse, would leave a more focused distribution and specialty business.
Comparable companies: CAH · COR · SYK · CI · CVS · ELV · MDLN · UNH
Open the interactive model, price chart and sensitivity grid →